NASDAQ: TRAW
Traws Pharma, Inc.CIK 0001130598 · Pharmaceutical Preparations
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade TRAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Traws Pharma launches antiviral program targeting Hantavirus and Ebola outbreaks
2 material changes detected. Sign up free to read the summary.
Traws Pharma updates ATM offering limit to $3.1M under baby shelf rules
3 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Traws Pharma reports Q1 2026 financial results in Regulation FD disclosure
2 material changes detected. Sign up free to read the summary.
Traws remedies control weaknesses, raises $10M as FDA halts lead drug; cash at $3.1M
5 material changes detected. Sign up free to read the summary.
Traws reports going-concern warning, Symbio termination, and Phase 2 COVID data
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.